如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01672 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | | 於下列日期開始時的結存(註1) ...

Group 1 - The company believes its current stock price is undervalued and has decided to increase the share buyback fund from a maximum of HKD 300 million to HKD 500 million as of December 15, 2025 [1] - The increase in buyback funds is attributed to significant achievements, including a 13-week Phase II study in the US showing a weight reduction of up to 7.7% for the oral small molecule GLP-1 agonist ASC30 in overweight or obese subjects, with better gastrointestinal tolerance [1] - The selective small molecule agonist ASC47, targeting thyroid receptor β (THRβ), showed a weight reduction improvement of up to 56.2% when combined with semaglutide compared to semaglutide alone in obese subjects [1] Group 2 - The company’s financial position is stable, and the board believes the current trading price does not reflect its intrinsic value [2] - The updated share buyback proposal is expected to enhance the value of the shares and increase shareholder returns, reflecting the company's confidence in its long-term business prospects and growth potential [2] - As of October 2, 2025, the company has utilized approximately HKD 54.28 million (excluding expenses) to repurchase 4.586 million ordinary shares under the buyback authorization [2]

格隆汇12月16日丨歌礼制药-B(01672.HK)发布公告，有关董事会拟根据公司股东于股东周年大会上授予 董事会购回公司股份的一般授权行使其权力，使用最多3亿港元的资金(拨付自公司内部财务资源)在合 适时间于公开市场上购回股份。 董事会认为公司现时股价被低估，并于2025年12月15日决议将股份购回资金由最多3亿港元增至最多5亿 港元("经更新建议股份购回")，此经考虑公司取得的重要里程碑的重大成就，包括但不限于：(1)歌礼口 服小分子GLP-1激动剂ASC30在肥胖或超重受试者中进行的美国13周II期研究显示经安慰剂校正后的体 重下降高达7.7%，且胃肠道耐受性更佳；(2)脂肪靶向甲状腺受体β(THRβ)选择性小分子激动剂ASC47与 司美格鲁肽联用在肥胖受试者中较司美格鲁肽单药减重效果相对提升高达56.2%；(3)有望成为同类最佳 口服小分子白细胞介素-17(IL-17)抑制剂ASC50美国I期研究取得积极的顶线结果；及(4)同类首创脂肪酸 合成酶(FASN)抑制剂地尼法司他(ASC40)治疗痤疮的新药上市申请获中国国家药品监督管理局受理。 于2025年12月15日，公司自2025年10月2日起根据购回 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容所產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Ascletis Pharma Inc. 歌禮製藥有限公司 （於開曼群島註冊成立的有限公司） （股份代號：1672） 自願性公告 擴大建議根據購回授權進行股份購回的規模 本公司現時的財務狀況穩健。董事會認為股份現時的成交價未能反映其內在價 值。董事會相信，經更新建議股份購回可提升股份的價值，從而提高股東的回 報。此外，董事會相信，經更新建議股份購回反映本公司對自身的長遠業務前景 及本公司的增長潛力充滿信心，且最終將可惠及本公司，並符合本公司及股東整 體的最佳利益。 1 經更新建議股份購回將以本公司除本公司二零一八年全球發售所得款項淨額及於 二零二五年八月二十五日完成的根據股東於二零二五年五月二十二日舉行的本公 司股東週年大會上授出的一般授權配售現有股份及補足認購新股份所得款項淨額 外之內部財務資源撥付。本公司不會在對本公司營運資金狀況造成重大不利影響 的情況下進行購回。本公司進行經更新建議股份購回時，將 ...

Group 1: Market Movements - Baoji Pharmaceutical-B (02659) surged over 3.2% amid its debut on the Hong Kong Stock Exchange, closing up 138.82% on its first day, with a market capitalization exceeding HKD 20 billion [1] - New Energy (01799) and Xinyi Solar (00968) saw declines of 3.01% and 3.67% respectively, as the photovoltaic sector faced weakness, with rumors of a 30 billion yuan investment for capacity storage by major companies [1] - Xpeng Motors-W (09868) and Li Auto-W (02015) dropped 4.88% and 2.67% respectively, following data from the China Association of Automobile Manufacturers indicating a month-on-month increase in production and sales [1] Group 2: Company-Specific News - Bolek Vision Cloud-B (02592) experienced a significant drop of nearly 15%, having previously doubled in price over 10 trading days, as it announced a new drug trial application to the FDA [2] - Hu Shang Ayi (02589) rose nearly 6% as Nayuki Tea expanded into the U.S. market, enhancing the international presence of Chinese tea brands [2] - Gold stocks fell sharply, with Zijin Mining (02899) and Shandong Gold (01787) declining by 4.29% and 4.94% respectively, following a report on the Bloomberg Commodity Index's upcoming rebalancing [2] Group 3: Cryptocurrency and Technology - Cryptocurrency ETFs faced significant declines, with notable drops in Bitcoin and Ethereum-related funds, as Bitcoin fell 3.3% from its record high, reflecting market pressures amid weak liquidity [3] - Oracle (ORCL.US) continued its downward trend, dropping 2.66% due to delays in delivering AI data centers for OpenAI, attributed to labor and material shortages [6] - Nvidia (NVDA.US) saw a slight increase of 0.73% after announcing the release of its third-generation language model, aimed at writing and programming tasks [6]

Core Viewpoint - Gilead Sciences-B (01672) shows a recovery of nearly 3%, with a current increase of 2.01% to HKD 13.2, and a trading volume of HKD 31.84 million [1] Group 1: Clinical Trial Results - On December 15, Gilead Sciences-B announced positive topline results from a randomized, double-blind, placebo-controlled Phase I clinical trial (NCT07024602) conducted in the United States [1] - The trial involved 46 healthy subjects who received single doses of ASC50 at varying strengths (10 mg, 30 mg, 100 mg, 200 mg, 400 mg, or 600 mg) or matching placebo [1] - The study aimed to evaluate the safety, tolerability, pharmacokinetics, and targeted binding characteristics of interleukin-17A (IL-17A) in peripheral circulation [1] Group 2: Product Information - ASC50 is an orally administered small molecule IL-17 targeted inhibitor developed by Gilead, which has been validated biologically and holds significant commercial value for various autoimmune and inflammatory diseases, including psoriasis [1] - ASC50 is classified as a new chemical entity (NCE) and is protected by patents in the U.S. and globally, with patent protection lasting until 2043 (excluding potential patent extensions) [1]

Core Viewpoint - The announcement from Gilead Sciences-B (01672) regarding positive results from the ASC50 clinical trial has led to a nearly 3% increase in stock price, reflecting investor optimism about the drug's potential in treating autoimmune diseases [1] Group 1: Clinical Trial Results - Gilead announced positive topline results from a Phase I clinical trial (NCT07024602) for ASC50, which was a randomized, double-blind, placebo-controlled study conducted in the United States [1] - The trial involved 46 healthy participants who received varying doses of ASC50 (10 mg, 30 mg, 100 mg, 200 mg, 400 mg, or 600 mg) or a matching placebo [1] - The study aimed to evaluate the safety, tolerability, pharmacokinetics, and targeted binding characteristics of ASC50 to interleukin-17A (IL-17A) [1] Group 2: Drug Information - ASC50 is an orally administered small molecule IL-17 targeted inhibitor developed by Gilead, which has shown biological validation and commercial potential in treating psoriasis and other autoimmune and inflammatory diseases [1] - ASC50 is classified as a new chemical entity (NCE) and is protected by patents in the U.S. and globally, with patent protection lasting until 2043, excluding potential extensions [1]

Company News - China Shenhua (01088.HK) reported coal sales of 389.5 million tons for the first 11 months, a decrease of 7.7% year-on-year. November sales were 37 million tons, down 3.6% year-on-year [1] - China Metallurgical Group (01618.HK) signed new contracts worth RMB 958.13 billion in the first 11 months, an 8.6% decrease year-on-year, with overseas contracts amounting to RMB 75 billion, a 0.4% increase year-on-year [1] - China Eastern Airlines (00670.HK) saw a 6.51% year-on-year increase in passenger capacity in November, with passenger turnover up 10.35% year-on-year and a seat load factor of 87.37%, up 3.04 percentage points year-on-year [1] - China Southern Airlines (01055.HK) reported an 8.68% year-on-year increase in passenger capacity in November, with passenger turnover up 10.42% year-on-year and a seat load factor of 86.29%, up 1.36 percentage points year-on-year [1] - New China Life Insurance (01336.HK) recorded cumulative original insurance premium income of RMB 188.85 billion for the first 11 months, a 16% year-on-year increase [1] - AOS Group (01161.HK) announced annual results for the year ending September 30, 2025, with revenue of approximately HKD 981 million, a decrease of 0.19% year-on-year, and a net profit of HKD 80.887 million, a 19% year-on-year increase [1] - Hopson Development Holdings (00754.HK) reported total contract sales of approximately RMB 14.27 billion for the first 11 months, an 8.91% decrease year-on-year [1] - Agile Group (01813.HK) had a pre-sale amount of RMB 511 million in November, a decrease of 21.4% year-on-year [1] - Galen Pharmaceuticals (01672.HK) is expected to become a best-in-class oral small molecule IL-17 inhibitor, with positive topline results from its Phase I study in the U.S. [1] - Bole Technology (02592.HK) submitted a new drug clinical trial application for CBT-199 to the U.S. FDA [1] - China Supply Chain Industry (03708.HK) signed a strategic cooperation framework agreement with Golden Energy regarding digital assets [1] - Times China Holdings (01233.HK) had its liquidation petition withdrawn [1] - Botai Car Union (02889.HK) received a first project designation notice from a leading domestic new energy vehicle client [1] Buyback Activities - Haijia Medical (06078.HK) plans to repurchase 10% of its issued shares, with a repurchase amount of no less than RMB 300 million [1] - Tencent Holdings (00700.HK) repurchased 1.051 million shares for HKD 636 million, with repurchase prices ranging from HKD 602.5 to HKD 608 [1] - Xiaomi Group (01810.HK) repurchased 7.2 million shares for HKD 302 million, with repurchase prices ranging from HKD 41.78 to HKD 42 [1] Share Cancellation - Pacific Shipping (02343.HK) canceled 23.739 million repurchased shares [2]

Core Viewpoint - The article highlights the positive topline results of ASC50, a novel oral small molecule IL-17 inhibitor developed by the company, from a Phase I clinical trial in the United States, indicating its potential as a best-in-class treatment for psoriasis and other autoimmune diseases [1][2][3] Group 1: Clinical Trial Results - ASC50 demonstrated a favorable safety profile and tolerability in a randomized, double-blind, placebo-controlled Phase I trial involving 46 healthy subjects [1] - The elimination half-lives of ASC50 after single oral doses of 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, and 600 mg were 43, 89, 91, 87, 104, and 85 hours respectively, supporting the potential for once-daily or possibly once-weekly dosing [1][2] - ASC50 exhibited significant target engagement, with elevated plasma IL-17A levels persisting up to 7 days post-administration at higher doses [2] Group 2: Pharmacokinetics and Comparison - ASC50 showed dose-proportional pharmacokinetic characteristics across the 10 mg to 600 mg dosing range [2] - In head-to-head studies with LY4100511, ASC50 demonstrated higher absolute oral bioavailability, greater drug exposure, longer half-life, and lower clearance rates [2] Group 3: Future Development and Market Potential - Based on the positive safety, tolerability, pharmacokinetics, and significant target engagement, ASC50 is advancing to the next phase of clinical development in patients with mild to moderate plaque psoriasis [2] - ASC50 is a new chemical entity (NCE) with patent protection in the U.S. and globally until 2043, excluding potential patent extensions, indicating strong commercial value [3] - The company emphasizes the encouraging data and the differentiated pharmacokinetic profile of ASC50, positioning it as a potential best-in-class oral small molecule IL-17 inhibitor [3]

Core Viewpoint - The announcement by the company regarding the positive topline results of the ASC50 Phase I clinical trial in the U.S. indicates significant advancements in the development of ASC50 as a targeted treatment for autoimmune and inflammatory diseases, particularly psoriasis [1][3]. Group 1: Clinical Trial Results - ASC50 demonstrated a favorable safety and tolerability profile in the single ascending dose (SAD) study, with all adverse events reported as mild (Grade 1) and of short duration, and no serious adverse events (SAEs) reported [2]. - The elimination half-lives of ASC50 after single oral doses of 10 mg, 30 mg, 100 mg, 200 mg, 400 mg, and 600 mg were 43, 89, 91, 87, 104, and 85 hours respectively, supporting the potential for once-daily or possibly once-weekly dosing [2]. - ASC50 exhibited significant targeted binding effects, with elevated plasma IL-17A levels persisting up to 7 days post-administration at higher doses [2]. Group 2: Pharmacokinetics and Comparison - The pharmacokinetic characteristics of ASC50 were found to be dose proportional across the 10 mg to 600 mg dosing range [2]. - In head-to-head studies with LY4100511, ASC50 showed higher absolute oral bioavailability, greater drug exposure, longer half-life, and lower clearance rates [2]. Group 3: Future Development and Market Potential - Based on the positive safety, tolerability, pharmacokinetics, and significant binding effects, ASC50 has progressed to the next phase of clinical development in patients with mild to moderate plaque psoriasis [3]. - ASC50 is a novel chemical entity (NCE) with U.S. and global compound patent protection until 2043, excluding potential patent extensions, indicating strong commercial value in the market [3]. - The company emphasizes the potential of ASC50 as a best-in-class oral small molecule IL-17 inhibitor, developed using AI-assisted structure-based drug discovery technology [3].